1. Home
  2. EVAX vs ENSC Comparison

EVAX vs ENSC Comparison

Compare EVAX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVAX
  • ENSC
  • Stock Information
  • Founded
  • EVAX 2008
  • ENSC 2003
  • Country
  • EVAX Denmark
  • ENSC United States
  • Employees
  • EVAX N/A
  • ENSC N/A
  • Industry
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • ENSC Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVAX Health Care
  • ENSC Health Care
  • Exchange
  • EVAX Nasdaq
  • ENSC Nasdaq
  • Market Cap
  • EVAX 8.7M
  • ENSC 7.9M
  • IPO Year
  • EVAX 2021
  • ENSC N/A
  • Fundamental
  • Price
  • EVAX $2.49
  • ENSC $5.80
  • Analyst Decision
  • EVAX Strong Buy
  • ENSC
  • Analyst Count
  • EVAX 3
  • ENSC 0
  • Target Price
  • EVAX $33.33
  • ENSC N/A
  • AVG Volume (30 Days)
  • EVAX 6.9M
  • ENSC 53.4K
  • Earning Date
  • EVAX 03-26-2025
  • ENSC 03-14-2025
  • Dividend Yield
  • EVAX N/A
  • ENSC N/A
  • EPS Growth
  • EVAX N/A
  • ENSC N/A
  • EPS
  • EVAX N/A
  • ENSC N/A
  • Revenue
  • EVAX $3,295,000.00
  • ENSC $4,421,404.00
  • Revenue This Year
  • EVAX $9,039.73
  • ENSC $89.78
  • Revenue Next Year
  • EVAX $1.47
  • ENSC N/A
  • P/E Ratio
  • EVAX N/A
  • ENSC N/A
  • Revenue Growth
  • EVAX N/A
  • ENSC 40.41
  • 52 Week Low
  • EVAX $2.22
  • ENSC $2.12
  • 52 Week High
  • EVAX $22.50
  • ENSC $14.85
  • Technical
  • Relative Strength Index (RSI)
  • EVAX 39.85
  • ENSC 38.42
  • Support Level
  • EVAX $2.30
  • ENSC $5.34
  • Resistance Level
  • EVAX $2.80
  • ENSC $6.46
  • Average True Range (ATR)
  • EVAX 0.51
  • ENSC 0.45
  • MACD
  • EVAX 0.03
  • ENSC -0.07
  • Stochastic Oscillator
  • EVAX 6.97
  • ENSC 20.08

About EVAX Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: